Noubar Afeyan, Flagship CEO (Victor Boyko/Getty Images for Aurora Humanitarian Initiative)

Flag­ship start­up Omega takes lead 'epige­nom­ic con­troller' can­di­date clos­er to the clin­ic with new $126M round

In its quest to drug the un­drug­gable, Flag­ship Pi­o­neer­ing start­up Omega Ther­a­peu­tics is chas­ing a moon­shot with “epige­nom­ic con­trollers” to get all of the ben­e­fits of gene edit­ing with­out the ac­tu­al edit­ing. That’s a tall task to craft a new class of ther­a­peu­tics, but in­vestors are cer­tain­ly show­ing in­ter­est.

Omega plans to ad­vance its lead can­di­date for the c-myc onco­gene in­to hu­man test­ing and es­tab­lish a man­u­fac­tur­ing foot­print with pro­ceeds from a $126 mil­lion Se­ries C the biotech closed Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.